Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Hum Exp Toxicol ; 40(12_suppl): S381-S396, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34569344

ABSTRACT

Aluminum phosphide (AlP) poisoning can be deadly in most cases targeting the heart. To overcome AlP toxicity, exenatide has been studied in the present study due to its pleiotropic effects on cardiac damages. In this study, the rats were exposed to LD50 of AlP (10 mg/kg) by gavage, and exenatide at doses (0.05, 0.1, and 0.2 mg/kg) injected intraperitoneally 30 min after poisoning. The cardiac parameters including heart rate (HR), blood pressure (BP), QRS, corrected QT (QTc), and ST were monitored for 180 min. Blood glucose level was measured in the study groups 30 min after exenatide injection. Evaluation of biochemical parameters including mitochondrial complexes I, II, and IV activities, adenosine diphosphate (ADP)/adenosine triphosphate (ATP) ratio, malondialdehyde (MDA), apoptosis, lactate, troponin I, and brain natriuretic peptide (BNP) was done on heart tissues after 12 and 24 h. Additionally, the tissues were analyzed for any pathological damages including necrosis, hemorrhage, or hyperemia 24 h post-treatment. Our results showed that AlP-induced HR, BP, and electrocardiographic changes were improved by exenatide at all doses. The blood glucose levels of poisoned animals reached control levels after exenatide treatment. Besides, treatment with exenatide at all doses improved complexes I and IV activity, ADP/ATP ratio, and apoptosis. Malondialdehyde, lactate, troponin I, and BNP levels were also diminished after exenatide co-treatment in poisoned animals. On the other hand, administration of exenatide doses improved the histopathology of AlP-induced tissues. Based on our findings, exenatide has a protective effect against phosphine-induced cardiotoxicity in an almost dose-dependent way. However, further investigations are needed on the potential clinical use of exenatide in this poisoning.


Subject(s)
Aluminum Compounds/toxicity , Blood Pressure/drug effects , Electrocardiography , Exenatide/pharmacology , Heart Rate/drug effects , Incretins/pharmacology , Phosphines/toxicity , Animals , Blood Glucose/drug effects , Dose-Response Relationship, Drug , Exenatide/administration & dosage , Lethal Dose 50 , Lipid Peroxidation , Male , Random Allocation , Rats , Rats, Wistar
2.
Fundam Clin Pharmacol ; 30(6): 502-510, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27473027

ABSTRACT

Neurologic sequelae remain a common and destructive problem in patients with acute kidney injury. The objective of this study was to evaluate the possible neuroprotective effect of erythropoietin (EPO) on motor impairments following bilateral renal ischemia (BRI) in two time points after reperfusion: short term (24 h) and long term (1 week). Male Wistar rats underwent BRI or sham surgery. EPO or saline administration was performed 30 min before surgery (1000 U/kg, i.p.). Explorative behaviors and motor function of the rats were evaluated by open field, rotarod, and wire grip tests. Plasma concentrations of blood urea nitrogen (BUN) and creatinine (Cr) were significantly enhanced in BRI rats 24 h after reperfusion. BRI group had only an increased level of BUN but not Cr 1 week after reperfusion. Impairment of balance function by BRI was not reversed by EPO 24 h after reperfusion, but counteracted 7 days after renal ischemia. Muscle strength had no significant differences between the groups. BRI group had a decrease in locomotor activity, and EPO could not reverse this reduction in both time points of the experiment. Although EPO could not be offered as a potential neuroprotective agent in the treatment of motor dysfunctions induced by BRI, it could be effective against balance dysfunction 1 week after renal ischemia.


Subject(s)
Erythropoietin/pharmacology , Locomotion/drug effects , Motor Disorders/drug therapy , Motor Disorders/etiology , Muscle Strength/drug effects , Neuroprotective Agents/pharmacology , Reperfusion Injury/complications , Acute Kidney Injury/complications , Animals , Blood Urea Nitrogen , Creatinine/metabolism , Disease Models, Animal , Male , Rats , Rats, Wistar , Reperfusion/methods
3.
Metab Brain Dis ; 30(1): 197-204, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25115607

ABSTRACT

Hepatic encephalopathy (HE) is a serious consequence of hepatic cirrhosis (HC). Previous studies have demonstrated cognitive impairments in both clinical and animal experiments of HC. Some potential therapeutic agents have been used to alleviate the cognitive symptoms in the animal models of HC. In the current study, the possible effect of erythropoietin (ERY) as a potent neuroprotective agent on motor and cognitive impairments induced by HC has been studied. Male Wistar rats (180-200 g) underwent bile duct ligation (BDL) or sham surgery. Administration of ERY (5,000 IU/kg, i.p., daily for three days) was initiated 2 weeks after surgery and lasted for the next 28 days. Open field, rotarod, Morris water maze and passive avoidance learning was used to evaluate the motor and cognitive function of the animals. ANOVA and repeated measures ANOVA were used to analyze the data. p < 0.05 was considered statistically significant. BDL rats had an increased level of hepatic enzymes and bilirubin. Impairment of balance function by BDL was reversed by ERY. Spatial and passive avoidance learning impairments observed in BDL rats were also reversed by chronic administration of ERY. ERY can be offered as a potential neuroprotective agent in the treatment of patients with HC that manifest mental dysfunctions. Though further studies are needed to clarify the exact mechanisms, the neuroprotective properties of ERY against BDL impairments were demonstrated in the current study.


Subject(s)
Erythropoietin/therapeutic use , Hepatic Encephalopathy/drug therapy , Learning Disabilities/prevention & control , Liver Cirrhosis, Experimental/drug therapy , Memory Disorders/prevention & control , Motor Activity/drug effects , Neuroprotective Agents/therapeutic use , Spatial Behavior/drug effects , Animals , Avoidance Learning/drug effects , Bile Ducts/surgery , Drug Evaluation, Preclinical , Erythropoietin/pharmacology , Exploratory Behavior/drug effects , Hand Strength , Hepatic Encephalopathy/etiology , Hepatic Encephalopathy/physiopathology , Hepatic Encephalopathy/psychology , Learning Disabilities/etiology , Ligation , Liver Cirrhosis, Experimental/complications , Male , Maze Learning/drug effects , Memory Disorders/etiology , Neuroprotective Agents/pharmacology , Rats , Rats, Wistar , Rotarod Performance Test
4.
Fundam Clin Pharmacol ; 29(1): 41-53, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24990322

ABSTRACT

Simvastatin (SV) leads to reduction of ventricular rhythm during atrial fibrillation on rabbit atrioventricular (AV) nodes. The aim of our study was (i) to determine the frequency-dependent effects of SV in a functional model, and (ii) to assess the effects of SV to suppress experimental AV nodal reentrant tachycardia (AVNRT). Selective stimulation protocols were used with two different pacing protocols, His to atrial, and atrial to atrial (AA). An experimental AVNRT model with various cycle lengths was created in three groups of perfused rabbit AV nodal preparations (n = 24) including: SV 3 µm, SV 7 µm, and verapamil 0.1 µm. SV increased nodal conduction time and refractoriness by AA pacing. Different simulated models of slow/fast and fast/slow reentry were induced. SV caused inhibitory effects on the slow anterograde conduction (origin of refractoriness) more than on the fast anterograde conduction time, leading to an increase of tachycardia cycle length, tachycardia wavelength and termination of slow/fast reentrant tachyarrhythmia. Verapamil significantly suppressed the basic and frequency-dependent intrinsic nodal properties. In addition, SV decreased the incidence of gap and echo beats. The present study showed that SV in a concentration and rate-dependent manner increased the AV effective refractory period and reentrant tachycardia wavelength that lead to slowing or termination of experimental fast AVNRT. The direction-dependent inhibitory effect of SV on the anterograde and retrograde dual pathways explains its specific antireentrant actions.


Subject(s)
Atrioventricular Node/drug effects , Simvastatin/pharmacology , Tachycardia, Atrioventricular Nodal Reentry/drug therapy , Tachycardia/drug therapy , Animals , Arrhythmias, Cardiac , Atrial Fibrillation/drug therapy , Brugada Syndrome , Cardiac Conduction System Disease , Electrocardiography/methods , Heart Conduction System/abnormalities , Heart Conduction System/drug effects , Heart Rate/drug effects , Male , Rabbits , Verapamil/pharmacology
5.
Eur J Pharmacol ; 714(1-3): 456-63, 2013 Aug 15.
Article in English | MEDLINE | ID: mdl-23850947

ABSTRACT

To improve cellular cardiomyoplasty efficacy after myocardial infarction (MI), we postulated that combining mesenchymal stem cells (MSCs) transplantation with anti-apoptotic and angiogenic effects of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) may provide better prognosis in an infarcted heart 48 rats, underwent left anterior descending artery ligation, were divided into eight groups and treated as follows: Group 1: MSC+EPO+VEGF, Group 2: MSC+EPO, Group 3: MSC+VEGF, Group 4: MSC, Group 5: EPO+VEGF, Group 6: EPO, Group 7: VEGF and Group 8: Control. After MI induction, EPO and VEGF were injected subcutaneously at the dose of 3000 U/kg and 3 µg/kg respectively. MSCs were transplanted one week after MI. In the fourteenth and sixteenth days after infarction, EPO was injected again. Echocardiography demonstrated that all treatments improved left ventricular function significantly (before vs. after treatment) but in control group ejection fraction deteriorated over the 2-months period. Percent of ejection fraction recovery in all treatment groups were significantly greater than control (P<0.05). Compared with the control group, all treatments attenuated cell death in peri-infarct areas significantly, except groups 6 and 7. Vascular density of all treatment groups were more than control group but this superiority was statistically significant only in group 1 (P<0.01). All of our treatments had beneficial effects to some extent but MSC transplantation combined with EPO and VEGF administration resulted in superior therapeutic outcome in enhancing cell survival and neovascularization.


Subject(s)
Cardiomyoplasty , Erythropoietin/therapeutic use , Mesenchymal Stem Cell Transplantation , Myocardial Infarction/therapy , Vascular Endothelial Growth Factor A/therapeutic use , Animals , Apoptosis/drug effects , Cell Culture Techniques , Cell Separation , Combined Modality Therapy , Electrocardiography , Erythropoietin/pharmacology , Male , Myocardial Infarction/diagnosis , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/pathology , Necrosis , Neovascularization, Physiologic/drug effects , Phenotype , Prognosis , Rats , Rats, Wistar , Treatment Outcome , Vascular Endothelial Growth Factor A/pharmacology
6.
Iran J Allergy Asthma Immunol ; 12(1): 86-92, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23454784

ABSTRACT

Severe congenital neutropenia (SCN) is a rare primary immunodeficiency disease. Different genes are found to be associated with SCN, including ELA2, HAX1, WAS, GFI1, G-CSFR and G6PC3. The aim of this study was to find different gene mutations responsible for SCN in Iranian patients. Twenty-seven patients with SCN referred to Immunology, Asthma and Allergy Research Institute during a five year priod 5 years (May 2007 and May 2012), were included in this study. Neutropenia related exons and flanking regions of ELA2, HAX1, WAS, GFI1, G-CSFR and G6PC3 were amplified by PCR and the sequences were analyzed. The results showed different mutations including 4 ELANE mutations, 11 HAX1 mutations and 2 G6PC3 mutations. None of the patients had GFI1 mutation and also one mutation was found in G-CSFR in a patient with ELANE mutation. Ten patients had unknown genetic diagnosis which was compatible with other studies. According to these results, most of the patients showed HAX1 mutations and this finding which significantly differed from other reports, might be related to differences in Iranian ethnicity and also in high rate of consanguineous marriages in Iran.


Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Glucose-6-Phosphatase/genetics , Leukocyte Elastase/genetics , Mutation , Neutropenia/congenital , Neutrophils/metabolism , 3' Flanking Region , 5' Flanking Region , Adolescent , Child , Congenital Bone Marrow Failure Syndromes , Consanguinity , Exons , Female , Humans , Iran , Male , Neutropenia/diagnosis , Neutropenia/genetics , Neutropenia/pathology , Neutrophils/pathology , Sequence Analysis, DNA
7.
Naunyn Schmiedebergs Arch Pharmacol ; 385(7): 697-706, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22538640

ABSTRACT

The purpose of the present study was to determine (1) whether simvastatin (SV) modifies the rate-dependent conduction time and refractoriness of the atrioventricular (AV) node and (2) how it can change the protective mechanism of the AV node during atrial fibrillation (AF). Predefined stimulation protocols were applied to detect the electrophysiological parameters of the AV node, including atrial-His conduction time, effective refractory period (ERP), functional refractory period (FRP), concealed conduction, excitable index, and fatigue in two groups of isolated, perfused rabbit AV nodal preparations (N=16). The stimulation protocols (fatigue, recovery) were carried out during control and in the presence of SV (0.5, 0.8, 3, and 10 µM). Simulated AF was executed in a separate group (N=8), and specific indexes, including H-H mean, zone of concealment (ZOC), and concealed beats were recorded. SV, in a concentration-dependent manner, prolonged ERP, FRP, and Wenckebach cycle lengths. It (10 µM) significantly increased fatigue and the excitable index. In addition, SV elicited prolongation of ZOC and H-H mean at 3 and 10 µM. SV-evoked prolongation of nodal refractoriness and concealed conduction caused rate-dependent ventricular slowing effects during AF. The ability of simvastatin to decrease the excitable gap by its heterogeneous effects on nodal dual pathways proposes its protective role in AF.


Subject(s)
Atrial Fibrillation/physiopathology , Atrioventricular Node/drug effects , Cardiotonic Agents/pharmacology , Heart Rate/drug effects , Simvastatin/pharmacology , Animals , Atrioventricular Node/physiology , Disease Models, Animal , In Vitro Techniques , Male , Rabbits
8.
Iran J Allergy Asthma Immunol ; 11(1): 51-6, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22427476

ABSTRACT

Severe congenital neutropenia is one of primary immunodeficiency disorders that characterized by severe neutropenia and is associated with severe systemic bacterial infections from early infancy. Granulocyte colony stimulating factor (GCSF) is clinically used as a treatment for congenital and acquired neutropenia. The aim of this study was evaluation of GCSF (PD- Grastim) in treatment of these patients. Patients with severe congenital neutropenia referred to Immunology, Asthma and Allergy Research Institute between Jan 2007 and Dec 2010 enrolled the study. Other causes of neutropenia were excluded by serial CBC and bone marrow studies, medical and drug histories and immunological tests. Patients were visited and examined monthly to evaluate their CBC and ANC (absolute neutrophil count), GCSF side effects and dosage adjustment. Cytogenetic studies were being done for all the patients for early detection of progression to AML/MDS. From twenty two patients who enrolled this study, 16 patients regularly evaluated. They were ten males and six females, range in age from 2 to 18 years old. Two patients failed to continue our follow up unfortunately and four patients died due to disease complications. Patients were followed for 24 to 48 months. In a period of 12-24 months before treatment, the mean of hospitalization frequency was 3.1 times and duration was 10 days; while during receiving treatment, they decreased to 0.2 times and 3 days, respectively (p<0.01). Also significant increase in mean ANC was observed during follow up (315/µl before treatment versus 1749/µl after 12 month regular treatment). Bone pain was the most common side effect. There have been no evidences of developing AML/MDS up to present time. Treatment with GCSF significantly reduced the duration and the frequency of hospitalization. Because of plausible progression to AML/MDS, regular follow-up of patients should be continued.


Subject(s)
Bacterial Infections/prevention & control , Granulocyte Colony-Stimulating Factor/therapeutic use , Neutropenia/congenital , Neutrophils/drug effects , Adolescent , Bacterial Infections/etiology , Child , Child, Preschool , Congenital Bone Marrow Failure Syndromes , Cytogenetic Analysis , Disease Progression , Female , Granulocyte Colony-Stimulating Factor/adverse effects , Hospitalization , Humans , Iran , Leukemia, Myeloid, Acute/etiology , Leukocyte Count , Male , Myelodysplastic Syndromes/etiology , Neutropenia/complications , Neutropenia/diagnosis , Neutropenia/drug therapy , Neutropenia/genetics , Neutropenia/mortality , Time Factors , Treatment Outcome
9.
Phytother Res ; 26(6): 826-32, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22072550

ABSTRACT

The study assessed the hydroalcohol extract effects of Crocus sativus L. (saffron) on (i) the basic and rate-dependent electrophysiological properties of the AV node, (ii) remodeling of the AV node during experimental atrial fibrillation (AF) and (iii) the role of nitric oxide (NO) in the effects of saffron on the AV node. Stimulation protocols in isolated AV node were used to quantify AV nodal recovery, facilitation and fatigue in four groups of rabbits (n = 8-16 per group). In addition, the nodal response to AF was evaluated at multiple cycle lengths and during AF. Saffron had a depressant effect on AV nodal rate-dependent properties; further, it increased Wenckebach block cycle length, functional refractory period, facilitation and fatigue (p < 0.05). A NO-synthase inhibitor (L-NAME) prevented the depressant effects of saffron on the AV node (p < 0.05). Saffron increased the zone of concealment in experimental AF (p < 0.05). The present research showed, for the first time, established electrophysiological remodeling of the AV node during AF by saffron. Saffron increased the AV nodal refractoriness and zone of concealment. These depressant effects of saffron were mediated by endogenous NO.


Subject(s)
Atrial Fibrillation/physiopathology , Atrioventricular Node/drug effects , Crocus/chemistry , Electrophysiological Phenomena , Nitric Oxide/metabolism , Animals , Anti-Arrhythmia Agents/pharmacology , Atrioventricular Node/metabolism , Atrioventricular Node/physiopathology , Ethanol , Fatigue/chemically induced , Fatigue/physiopathology , Heart Block/physiopathology , Heart Rate , In Vitro Techniques , Male , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide/antagonists & inhibitors , Plant Extracts/administration & dosage , Plant Extracts/chemistry , Plant Extracts/pharmacology , Rabbits , Water
10.
Int. j. morphol ; 28(3): 653-658, Sept. 2010. ilus
Article in English | LILACS | ID: lil-577167

ABSTRACT

Reducing the infarct size in acute myocardial infarction is one of the most important goals driving new drug research and development. During the last two decades, many clinical studies have found cardioprotective effects of corticosteroids, but their exact role in ischemic preconditioning remains questionable. The aim of the present study was to determine the protective effects of hydrocortisone sodium succinate on myocardial preconditioning in rabbit hearts. Twenty-four male New Zealand rabbits were divided randomly & equally in four groups: 1) control, 2) Infarct, 3) Ischemic preconditioning (IP) and 4) Hydrocortisone (HYD). The HYD group received 50mg/kg Hydrocortisone 45min before major ischemia. Serum levels of cardiac troponin-T(cTNT) and cortisole were measured before and after the protocols. Triphenyl-tetrazolium chloride staining was used to determine the infarcted area. In the present study, exogenous hydrocortisone decreased infarct size by 53 percent in comparison to the infarct group. Serum level of cortisole was increased in the IP and HYD groups, and was significant in the HYD group (p<0.01). An increasing trend in cortisole level was associated with a decreasing trend in infarct size and cTNT in the IP and HYD groups (p>0.01). In conclusion, we showed that hydrocortisone has cardioprotective effects when injected before the onset of myocardial infarction. In addition, we have proposed for the first time that endogenous hydrocortisone may play a role in ischemic preconditioning phenomena.


La reducción del tamaño del infarto en el infarto agudo de miocardio es una de las metas más importantes que impulsan la investigación y el desarrollo de nuevos fármacos. Durante las dos últimas décadas, muchos estudios clínicos han encontrado efectos cardioprotectores de los corticosteroides, pero su papel exacto en el preacondicionamiento isquémico sigue siendo cuestionable. El objetivo del presente estudio fue determinar los efectos protectores de succinato sódico de hidrocortisona en el preacondicionamiento del miocardio en el corazón de conejo. Veinticuatro conejos neozelandeses machos fueron divididos al azar en cuatro grupos : 1) control, 2) infarto, 3) preacondicionamiento isquémico (PI) y 4) Hidrocortisona (HYD). El grupo HYD recibió 50 mg/kg de hidrocortisona 45 minutos antes de la isquemia mayor. Los niveles séricos de troponina cardíaca T (cTNT) y cortisol se midieron antes y después de los protocolos. Se utilizó la tinción cloruro de trifenil-tetrazolio para determinar el área infartada. En el presente estudio, la hidrocortisona exógena disminuyó el tamaño del infarto en un 53 por ciento en comparación con el grupo de infarto. Los niveles séricos de cortisol se incrementaron en los grupos IP y HYD, siendo significativa en el grupo de HYD (p <0,01). Un aumento en el nivel cortisol se asoció con la disminución del tamaño del infarto y la cTNT en los grupos IP y HYD (p> 0,01). En conclusión, hemos demostrado la hidrocortisona tiene efectos cardioprotectores cuando se inyecta antes de la aparición del infarto al miocardio. Además, hemos propuesto, por primera vez que la hidrocortisona endógena puede jugar un papel en los fenómenos de preacondicionamiento isquémico.


Subject(s)
Animals , Rabbits , Protective Agents/pharmacology , Heart , Reperfusion Injury/prevention & control , Hydrocortisone/pharmacology , Myocardial Infarction/prevention & control , Ischemic Preconditioning, Myocardial , Disease Models, Animal , Reperfusion Injury/drug therapy , Reperfusion Injury/blood , Hydrocortisone/blood , Myocardial Infarction/drug therapy , Myocardial Infarction/blood , Troponin T/blood
11.
Int. j. morphol ; 28(2): 445-451, June 2010. ilus
Article in English | LILACS | ID: lil-577136

ABSTRACT

Treatment of supraventricular arrhythmia includes a wide range of medical interventions. Herbal remedies are suitable alternatives to synthetic drugs due to their availability, minimal side effects and lower price. Pharmacological studies and traditional medical literature point to the cardiovascular effects of Citrus aurantium L. (Rutaceae) in many instances. In the present study we used isolated perfused AV-node of rabbit as an experimental model to determine the effect of various concentrations of essential oil of C. aurantium (0.1-0.3 v/v) on the nodal conduction time and refractoriness of an isolated rabbit AV-nodal preparations. Selective stimulation protocols were used to independently quantify AV nodal recovery, facilitation and fatigue in 18 rabbits. Our results showed concentration-dependent and rate-independent suppressive effects of essence of C. aurantium on the Wenchebach cycle length (WBCL), AV Conduction Time (AVCT) and effective and functional refractory periods (ERP & FRP). Functional properties such as facilitation and fatigue were significantly increased by this plant. Citrus aurantium plays a protective role against the toxic effects of ouabaine by increasing AV nodal conduction time and refractoriness. The above results indicated differential effects of C. aurantium on slow and fast pathways, with a dominant role on fast pathways. This research has explained the protective role of C. aurantium on ouabaine toxicity. All results indicated the potential anti-arrhythmic effects of C. aurantium in treating supraventricular tachyarrhythmia.


El tratamiento de la arritmia supraventricular incluye una amplia gama de intervenciones médicas. Los remedios herbarios son alternativas adecuadas a las drogas sintéticas debido a su disponibilidad, con escasos efectos secundarios y bajo precio. Estudios farmacológicos y la literatura médica tradicional señalan los efectos cardiovasculares de Citrus aurantium L. (Rutaceae) en muchos casos. En el presente estudio se usaron aislados perfundidos del nodo AV de conejo como modelo experimental para determinar el efecto de diferentes concentraciones de aceite esencial de C. aurantium (0,1-0,3 v/v) sobre en el tiempo de conducción nodal y refractariedad. Un protocolo de estimulación selectiva se utilizó para cuantificar de forma independiente la recuperación, la facilitación y la fatiga del nodo AV en 18 conejos. Nuestros resultados muestran efectos supresores dependientes de la concentración e independiente de la velocidad de la esencia de C. aurantium sobre la duración del ciclo Wenchebach (WBCL), tiempo de conducción AV (AVTC) y períodos refractarios eficaz y funcional (PRE y PRF). Propiedades funcionales tales como la facilitación y la fatiga se incrementaron de manera significativa por esta planta. La Citrus aurantium juega un papel protector contra los efectos tóxicos de ouabaína al incrementar el tiempo de conducción AV nodal y la refractariedad. Los resultados indican efectos diferenciales de C. aurantium sobre las vías lentas y rápidas, con un papel dominante en las vías rápidas. Esta investigación ha explicado el papel protector de C. aurantium sobre la toxicidad ouabaine. Todos los resultados indican los posibles efectos anti-arrítmicos de C. aurantium en el tratamiento de taquiarritmias supraventriculares.


Subject(s)
Animals , Rabbits , Oils, Volatile/pharmacology , Citrus/chemistry , Atrioventricular Node , Ouabain/antagonists & inhibitors , Arrhythmias, Cardiac/drug therapy , Cardiac Electrophysiology , Ouabain/toxicity , Plant Preparations/pharmacology , Time Factors
12.
Saudi Med J ; 29(3): 357-63, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18327359

ABSTRACT

OBJECTIVE: To evaluate concentration-dependent effects of total extract of Ruta graveolens and its purified alkaloid fraction on the nodal basic and functional properties. METHODS: In the present experimental study, we used the Langendorff model for perfusion of isolated rat hearts to determine the effects of various concentrations of methanolic extract of Rue (1.25 x 10(-6) % weight per volume percent [W/V]; 2.5 x 10(-6) % W/V; 3.75 x 10(-6) % W/V) and total alkaloid of Rue (0.25 x 10(-6) % W/V; 0.5 x 10(-6) % W/V) on electrophysiological properties of cardiac tissue. Selective stimulation protocols were used to independently quantify atrioventricular AV nodal recovery, facilitation, and fatigue. We used 3 groups (N=24) of isolated perfused rat AV nodal preparations to assess the effect of Rue extracts. The study was carried out in October 2006 in the electrophysiology laboratory of the Cardiovascular Research Center of Golestan University of Medical Sciences, Golestan, Gorgan, Iran. RESULTS: Our results showed that both the total plant extract and the alkaloid fraction of Ruta graveolens had a similar trend of action on nodal conduction time and refractoriness. Furthermore, we observed increased atrioventricular conduction time (83+/-4 to 108+/-5) msec and functional refractory period (157.6+/-3 to 163.7+/-4 msec) at a maximum concentration of 3.75 x 10(-6) % W/V. CONCLUSION: The above results indicated a potential antiarrhythmic effect of Ruta graveolens in treating supra ventricular tachyarrhythmia.


Subject(s)
Atrioventricular Node/drug effects , Plant Extracts/pharmacology , Ruta , Animals , Anti-Arrhythmia Agents , Electrophysiology , Male , Rats , Rats, Sprague-Dawley , Time Factors
13.
J Infus Nurs ; 27(4): 255-61, 2004.
Article in English | MEDLINE | ID: mdl-15273633

ABSTRACT

Positive fluid balance in critically ill patients is a common problem in the intensive care unit (ICU) often associated with a poor outcome. In addition, clinically important changes in hemodynamic variables have been found to occur after diuretic therapy. This study was conducted to evaluate the safety and relative effectiveness of two diuretic protocols in the ICU. Twenty-two patients in the medical ICU with pulmonary edema or fluid overload and PaO2/FIO2 pressure less than 300, were randomized to diuretic therapy by either continuous infusion or intermittent bolus. Hemodynamic and biochemical measurements were recorded. Protocol-guided diuretic management can be readily and safely implemented in the ICU. Although both continuous and bolus diuretic regimens appear to be equally effective in achieving negative fluid balance, the clinician may consider a continuous infusion of furosemide in the hemodynamically and electrolytically unstable patient to ensure more controlled diuresis with less hemodynamic and electrolyte alteration. From a nursing perspective, a continuous infusion of furosemide is a more efficient means of drug delivery.


Subject(s)
Diuretics/administration & dosage , Furosemide/administration & dosage , Infusions, Intravenous/methods , Analysis of Variance , Diuretics/pharmacology , Furosemide/pharmacology , Hemodynamics/drug effects , Humans , Prospective Studies , Water-Electrolyte Balance/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...